Hormone replacement therapy (HRT) is one of the most effective ways to prevent osteoporosis after menopause. It reduces hip fracture risk by roughly 50% and vertebral fracture risk by 50% to 80% when taken for five years or more. These numbers make HRT comparable to dedicated bone-strengthening medications, with the added benefit of treating menopause symptoms at the same time.
How Estrogen Protects Your Bones
Your skeleton is constantly being broken down and rebuilt. Specialized cells called osteoclasts dissolve old bone, while osteoblasts lay down new bone to replace it. Before menopause, estrogen keeps this cycle balanced by blocking the chemical signal (RANKL) that activates bone-dissolving cells. It also promotes a decoy receptor that intercepts that signal before it can do its job. On the building side, estrogen supports the survival and activity of bone-forming cells through a separate signaling pathway.
When estrogen levels drop at menopause, bone breakdown accelerates sharply. The fastest bone loss happens in the first three to four years after menopause, which is why timing matters so much for prevention. Without intervention, women in this early postmenopausal window can lose significant bone density before they even realize it’s happening.
How Much Bone Loss HRT Actually Prevents
In clinical trials, HRT increased bone mineral density in the spine by about 7% and in the hip by nearly 5% over four years. For context, women in the same trial who took only calcium and vitamin D lost 2.5% in the spine and 4.4% in the hip over that same period. That swing from loss to gain represents a meaningful difference in fracture risk.
The fracture reduction numbers are striking. Epidemiological data suggest HRT cuts nonvertebral fracture risk by 35% to 50% when started before age 60. Five or more years of use is associated with a 50% to 80% reduction in vertebral fractures and a 25% reduction in wrist fractures. The Women’s Health Initiative, one of the largest randomized trials ever conducted in postmenopausal women, confirmed that both estrogen-only and combined estrogen-progestogen therapy prevent osteoporotic fractures.
The Window That Matters Most
HRT provides its greatest bone protection when started before age 60 or within 10 years of menopause. This is often called the “timing hypothesis,” and it aligns with the biology: bone resorption is fastest in those early postmenopausal years, so intervening early catches the period when the most bone would otherwise be lost. Starting HRT during this window means the therapy can halt rapid breakdown and allow the natural rebuilding process to fill in, producing a significant increase in bone density.
Starting HRT later than 10 years after menopause is generally not recommended as a first-line approach for bone health. At that point, other medications designed specifically for osteoporosis may be more appropriate, and the risk-benefit profile of HRT shifts.
How HRT Compares to Other Bone Medications
Bisphosphonates are the most commonly prescribed drugs for osteoporosis, and they work through a different mechanism: poisoning the bone-dissolving cells directly rather than modulating hormones. In a four-year head-to-head trial, HRT and a bisphosphonate produced similar spine density gains (7.0% vs. 7.3%), but HRT was notably better at the hip (4.8% vs. 0.9%). Combining the two produced the best results of all: a 10.4% increase in spine density and 7.0% at the hip.
The practical difference is that HRT treats the whole constellation of menopause symptoms (hot flashes, sleep disruption, vaginal dryness) while also protecting bone, making it a cost-effective choice for symptomatic women who are also at risk for osteoporosis. Bisphosphonates, on the other hand, do nothing for menopause symptoms but can be used safely by women well past the HRT timing window.
Dose and Delivery Method
Not all doses of estrogen protect bone equally. Research on transdermal patches (the type you wear on your skin) found that a standard dose of 0.05 mg per day of estradiol was effective at counteracting postmenopausal bone loss. Dropping to 0.025 mg per day, however, was not enough to prevent bone demineralization. Women on the lower dose initially gained bone density at the higher dose, then lost it again when stepped down, with cortical bone dropping 2.4% and trabecular bone dropping 3.6% over six months at the inadequate dose.
This means there is a threshold below which estrogen simply doesn’t do enough to keep bone-dissolving cells in check. Your prescriber will typically aim for the lowest effective dose that still protects bone and manages symptoms.
The Role of Progestogen
Women who still have a uterus need a progestogen alongside estrogen to protect the uterine lining. The type of progestogen may matter for both bone health and overall safety. Studies of estrogen combined with medroxyprogesterone (a synthetic progestogen) show slightly greater bone density increases compared to estrogen alone, suggesting an additive bone benefit.
From a safety standpoint, the choice of progestogen is worth discussing with your prescriber. A large French observational study following 80,000 women over eight years found that the combination of estrogen with micronized progesterone (a form closer to the body’s own hormone) was not associated with increased breast cancer risk, while estrogen combined with synthetic progestins was. This distinction is increasingly influencing prescribing patterns.
What Happens When You Stop
One important limitation of HRT for bone health: the protection doesn’t last after you stop. Data from the PEPI follow-up study showed that women who discontinued long-term HRT lost bone at a rate of about 1% per year at both the hip and spine. Women who had only taken HRT for one year before stopping lost bone somewhat more slowly (around 0.5% to 0.8% per year), but the direction was the same.
This means HRT delays osteoporosis rather than permanently preventing it, unless you continue therapy indefinitely. For many women, the practical approach is to use HRT during the early postmenopausal years when symptoms are worst and bone loss is fastest, then transition to a bisphosphonate or another bone-specific treatment if ongoing protection is needed. Some women and their prescribers decide that extended HRT use is appropriate, weighing the bone and symptom benefits against individual risk factors.
Who Benefits Most
HRT for bone protection makes the most sense for women who are under 60, within 10 years of menopause, experiencing menopause symptoms, and at risk for osteoporosis due to family history, low body weight, or early menopause. In this group, HRT addresses multiple problems at once and is considered cost-effective compared to using separate treatments for symptoms and bone loss.
Women with a personal history of breast cancer, blood clots, stroke, or liver disease typically need alternative bone-protection strategies. For women who are past the timing window or have no menopause symptoms, dedicated osteoporosis medications are usually the better fit, since they carry fewer of the risks associated with systemic hormone use.